271 related articles for article (PubMed ID: 20858843)
1. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.
Rosenblat TL; McDevitt MR; Mulford DA; Pandit-Taskar N; Divgi CR; Panageas KS; Heaney ML; Chanel S; Morgenstern A; Sgouros G; Larson SM; Scheinberg DA; Jurcic JG
Clin Cancer Res; 2010 Nov; 16(21):5303-11. PubMed ID: 20858843
[TBL] [Abstract][Full Text] [Related]
2. Targeted alpha-particle immunotherapy for acute myeloid leukemia.
Jurcic JG; Rosenblat TL
Am Soc Clin Oncol Educ Book; 2014; ():e126-31. PubMed ID: 24857092
[TBL] [Abstract][Full Text] [Related]
3. Targeted Alpha-Particle Therapy for Hematologic Malignancies.
Jurcic JG
J Med Imaging Radiat Sci; 2019 Dec; 50(4 Suppl 1):S53-S57. PubMed ID: 31253514
[TBL] [Abstract][Full Text] [Related]
4. Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.
Jurcic JG
Curr Radiopharm; 2018; 11(3):192-199. PubMed ID: 29793418
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab.
Rosenblat TL; McDevitt MR; Carrasquillo JA; Pandit-Taskar N; Frattini MG; Maslak PG; Park JH; Douer D; Cicic D; Larson SM; Scheinberg DA; Jurcic JG
Clin Cancer Res; 2022 May; 28(10):2030-2037. PubMed ID: 35247915
[TBL] [Abstract][Full Text] [Related]
6. Targeted alpha particle immunotherapy for myeloid leukemia.
Jurcic JG; Larson SM; Sgouros G; McDevitt MR; Finn RD; Divgi CR; Ballangrud AM; Hamacher KA; Ma D; Humm JL; Brechbiel MW; Molinet R; Scheinberg DA
Blood; 2002 Aug; 100(4):1233-9. PubMed ID: 12149203
[TBL] [Abstract][Full Text] [Related]
7. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.
Feldman EJ; Brandwein J; Stone R; Kalaycio M; Moore J; O'Connor J; Wedel N; Roboz GJ; Miller C; Chopra R; Jurcic JC; Brown R; Ehmann WC; Schulman P; Frankel SR; De Angelo D; Scheinberg D
J Clin Oncol; 2005 Jun; 23(18):4110-6. PubMed ID: 15961759
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia.
Sekeres MA; Lancet JE; Wood BL; Grove LE; Sandalic L; Sievers EL; Jurcic JG
Haematologica; 2013 Jan; 98(1):119-28. PubMed ID: 22801961
[TBL] [Abstract][Full Text] [Related]
9. Targeted Alpha-Particle Therapy for Hematologic Malignancies.
Jurcic JG
Semin Nucl Med; 2020 Mar; 50(2):152-161. PubMed ID: 32172800
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
[TBL] [Abstract][Full Text] [Related]
11. Antibody therapy of acute myelogenous leukemia.
Jurcic JG
Cancer Biother Radiopharm; 2000 Aug; 15(4):319-26. PubMed ID: 11041016
[TBL] [Abstract][Full Text] [Related]
12. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
[TBL] [Abstract][Full Text] [Related]
13. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial.
Raza A; Jurcic JG; Roboz GJ; Maris M; Stephenson JJ; Wood BL; Feldman EJ; Galili N; Grove LE; Drachman JG; Sievers EL
Leuk Lymphoma; 2009 Aug; 50(8):1336-44. PubMed ID: 19557623
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
[TBL] [Abstract][Full Text] [Related]
15. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.
Caron PC; Dumont L; Scheinberg DA
Clin Cancer Res; 1998 Jun; 4(6):1421-8. PubMed ID: 9626458
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD33-antibodies labelled with the alpha-emitter Bismuth-213 kill CD33-positive acute myeloid leukaemia cells specifically by activation of caspases and break radio- and chemoresistance by inhibition of the anti-apoptotic proteins X-linked inhibitor of apoptosis protein and B-cell lymphoma-extra large.
Friesen C; Roscher M; Hormann I; Leib O; Marx S; Moreno J; Miltner E
Eur J Cancer; 2013 Jul; 49(11):2542-54. PubMed ID: 23684782
[TBL] [Abstract][Full Text] [Related]
17. Where do we stand with radioimmunotherapy for acute myeloid leukemia?
Walter RB
Expert Opin Biol Ther; 2022 May; 22(5):555-561. PubMed ID: 35350938
[TBL] [Abstract][Full Text] [Related]
18. Antibody therapy for residual disease in acute myelogenous leukemia.
Jurcic JG
Crit Rev Oncol Hematol; 2001 Apr; 38(1):37-45. PubMed ID: 11255080
[TBL] [Abstract][Full Text] [Related]
19. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
[TBL] [Abstract][Full Text] [Related]
20. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
